| Course | DDBA 8562 Seminar in Law and Ethics in Healthcare Management |
|---|---|
| Week | Week 9 |
| Paper type | Conflicts note |
| Length | About 510 words, 4 pages |
| Format | APA 7 student paper |
| School | Walden University |
| Program | Doctor of Business Administration (DBA) |
| Updated | October 2026 |
Free sample paper for DDBA 8562 Week 9
Before the Committee Votes on Spinal Implants: A Conflicts Note on a Surgeon Lead Who Consults for One Bidder, Setting the Federal Payment Reporting Law, Which Permits the Relationship Once Disclosed, Against the System's Recusal Policy
Student Name
Walden University
DDBA 8562: Seminar in Law and Ethics in Healthcare Management
Instructor Name
Month Day, Year
Before the Committee Votes on Spinal Implants: A Conflicts Note on a Surgeon Lead Who Consults for One Bidder, Setting the Federal Payment Reporting Law, Which Permits the Relationship Once Disclosed, Against the System's Recusal Policy
The Decision, the Member and the Interest
On November 4, 2026, the value analysis committee of a composite health system in Tennessee will choose a single vendor for spinal fusion implants, a contract worth about $6.8 million over three years. The committee's surgeon lead, an orthopedic spine surgeon, has a consulting relationship with one of the three bidders. The federal Open Payments database reports that the bidder paid the surgeon $86,400 in consulting fees and $12,300 in travel and lodging in program year 2024, and $71,900 in consulting fees in program year 2025. This note is written on October 20, before the vote.
The Federal Reporting Law
The Physician Payments Sunshine Act requires manufacturers of drugs, devices and medical supplies covered by federal health programs to disclose money and other things of value they give to physicians and teaching hospitals, which the Centers for Medicare and Medicaid Services publish (Transparency reports and reporting of physician ownership or investment interests, 42 U.S.C. § 1320a-7h). The statute does not prohibit the payments. It requires that they be reported. Under federal law, the surgeon's relationship is lawful once reported.
The System's Policy
The system's conflict-of-interest policy requires any committee member with a financial interest above $5,000 a year in a company affected by a decision to disclose it and to recuse from deliberation and voting on that decision. On the policy's terms, disclosure is not enough. The surgeon must step aside from the implant decision.
The policy reflects an argument made in the national report on medical conflicts of interest (Institute of Medicine, 2009) on conflicts of interest in medicine: that disclosure is necessary but often insufficient, and that some conflicts must be managed or eliminated rather than merely revealed. Experimental evidence supports that caution. Cain et al. (2005) ran experiments in which advisors paid to skew their estimates did so more after revealing their conflict, while those receiving the advice adjusted for it too little. The finding comes from laboratory experiments with students, not from hospital committees, so it suggests rather than proves how disclosure works in this setting.
What the Committee Should Do
The surgeon should recuse from the deliberation and vote, as the policy requires, and the committee should still hear the surgeon's clinical assessment of the implants, in writing and identified as coming from a member with a disclosed interest, so that expertise is not lost. A second spine surgeon without industry payments should review the clinical comparison. The recusal and the reason should be recorded in the minutes.
If the Surgeon Objects
If the surgeon objects that recusal wastes the committee's best expertise, the written assessment answers that concern without giving a conflicted member a vote.
Why Now
A conflict discovered after the contract is signed can only be explained; one addressed before the vote can be managed.
References
Cain, D. M., Loewenstein, G., & Moore, D. A. (2005). The dirt on coming clean: Perverse effects of disclosing conflicts of interest. Journal of Legal Studies, 34(1), 1-25. https://doi.org/10.1086/426699
Institute of Medicine. (2009). Conflict of interest in medical research, education, and practice. National Academies Press.
Transparency reports and reporting of physician ownership or investment interests, 42 U.S.C. § 1320a-7h (2018).
The Walden DDBA 8562 Week 9 instructions
Week 9 asks for a short note on a conflict of interest, dated before the decision it concerns. Name the decision, the member and the interest, quantifying the interest from a public source with program years. Describe the transparency law accurately, including what it permits. State the organization's policy as a second authority with a different view of disclosure. Bring in literature on whether disclosure is enough, stating the findings precisely and their limits. Recommend what the committee should do, preserving expertise where possible, and explain why acting before the vote matters. Record the recusal and its reason in the minutes.
Inside the DDBA 8562 Week 9 example
The sample's first section gives the contract value, the vote date and the Open Payments figures by year. The federal section explains that manufacturers report payments, the government publishes them and the statute does not prohibit them. The policy section requires disclosure and recusal above $5,000. A paragraph reports the national report's view that disclosure is necessary but often insufficient and the experimental finding that disclosing advisors gave more biased advice that recipients did not discount enough, noting the experiments used students. The recommendation is recusal from deliberation and vote, a written clinical assessment labeled as coming from a conflicted member and review by a second surgeon. A closing line explains that a conflict addressed before the vote can be managed, while one found afterward can only be explained. A second unconflicted surgeon reviews the comparison.
DDBA 8562 Week 9 rubric: what earns full marks
Timing is checked first: a note dated after the decision, or framed as a retrospective, has misunderstood the genre and forfeits the portion reserved for early visibility. The interest must be quantified from a public source; a note relying on the member's own disclosure form collects less. Accurate characterization of the transparency statute carries its own allocation, since overstating it as a prohibition is common. The literature paragraph earns doctoral credit when findings are stated precisely with their experimental limits. A recommendation that manages the conflict while keeping useful expertise shows judgment. A short, plainly written note that committee members can read before the meeting is the genre's purpose.
DDBA 8562 Week 9 help: mistakes that cost marks
Search the Open Payments database for the member's name and record payments by type and year. Read the statute's reporting requirement and note what it does not prohibit. Find your organization's conflict policy and its threshold. Read one study of disclosure's effects and report its design honestly. Recommend concrete steps: recusal, written input, independent review and minutes. Date the note before the decision. Keep it to two or three pages, since its purpose is to be read before the meeting. If the member objects to recusal, explain how written input preserves the expertise without a vote. Note the date clearly at the top.
Get a DDBA 8562 Week 9 example written to your instructions
The Week 9 scenario, your prompt and the section rubric are the inputs; add the conflict-of-interest policy text if the classroom supplied one. A note written to that policy comes back within 24 to 48 hours, and the first costs nothing. Scenarios built on a board member's financial stake rather than a clinician's consulting fees follow the same design.
More DDBA 8562 papers and DBA samples
- DDBA 8562 Week 1: Competing Duties Discussion
- DDBA 8562 Week 2: EMTALA Authority Brief
- DDBA 8562 Week 3: Prima Facie Duties Note
- DDBA 8562 Week 4: Dual Obligation Case Analysis
- DDBA 8562 Week 5: Duty to Protect Analysis
- DDBA 8562 Week 6: Board Oversight Case
- DDBA 8562 Week 7: Physician Noncompete Case
- DDBA 8562 Week 8: Compliance Effectiveness Memo
- DDBA 8562 Week 10: Error Disclosure Position Paper
- DDBA 8562 Week 11: Conflicting Duties Seminar Paper
- DDBA 8561 Week 9: Paired Measurement Note
- DDBA 8560 Week 9: Sequenced Implementation Plan
- DDBA 8541 Week 9: Sample Frame Appraisal
- DDBA 8531 Week 9: Relationship Literature Appraisal
DDBA 8562 Week 9 questions, answered
Where can I find a free DDBA 8562 Week 9 sample paper?
The implant committee conflicts note is reproduced on this page, free.
What conflict does the DDBA 8562 Week 9 note address?
A committee's surgeon lead who consults for one of three spinal implant bidders.
How large is the interest?
$86,400 in consulting fees and $12,300 in travel in 2024, and $71,900 in consulting fees in 2025.
Does federal law prohibit the relationship?
No; the Sunshine Act requires the payments to be reported but permits them.
What does the note recommend?
Recusal from deliberation and vote, with a written clinical assessment and review by an unconflicted surgeon.